The two RET fusion genes described here leading to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the ...

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

which has so far been approved by the FDA for RET-positive thyroid and non-small cell lung cancer (NSCLC). By far, the majority of RET-positive cancers are lung and thyroid tumours, but the ...

Gavreto (pralsetinib) has been cleared as a first-line treatment of people with RET fusion-positive advanced non-small cell lung cancer (NSCLC), a disease that is diagnosed in around 37,000 people ...